In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.
